- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT05629689
Tutkimus GEH200520/GEH200521 (18F) turvallisuuden ja siedettävyyden arvioimiseksi käytettäessä PET-skannauksia potilailla, joilla on kiinteitä kasvaimia.
Vaihe 1a/1b, monikeskus, avoin, annoksen suurennus- ja annoksen laajennustutkimus potilailla, joilla on kiinteitä kasvainpahanlaatuisia kasvaimia GEH200520-injektion / GEH200521 (18F) injektion turvallisuuden ja siedettävyyden arvioimiseksi, PET-kuvantaminen, farmakokinetiikassa ja muutoksissa Kuvaus hoidon jälkeen
Part A: The purpose of this part is to assess the safety of GEH200520 and GEH200521 (18F) when administered to patients with solid cancer. Subjects will be requested to complete 3 study visits: 1 screening visit, 1 imaging visit (over 24 hours) and 1 follow-up visit (7 days later). The estimated duration of Part A is 21 days.
Part B: The purpose of this part of the study is to assess the imaging quality and findings as well as the safety and tolerability of GEH200520 and GEH200521 (18F) when administered to patients with cancer before and after immunotherapy treatment.
Subjects will be requested to complete 7 study visits: 1 screening visit, the first imaging visit, followed by 2 immunotherapy immune-checkpoint inhibitor (ICI) treatment visits and 2 additional imaging and 1 follow-up visit. Two late imaging transfer expected post follow up visit. The estimated duration for subject participation in Part B is approximately 64 days.
Tutkimuksen yleiskatsaus
Tila
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Vaihe 1
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Amsterdam, Alankomaat
- Amsterdam UMC
-
Groningen, Alankomaat
- UMC Groningen
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- The subject is able and willing to comply with all study procedures as described in the protocol, including the imaging day pre-visit requirements, and has read, signed, and dated an informed consent form prior to any study procedures being performed.
- The subject is male or female, ≥18 years of age.
- Subject has a life expectancy ≥12 weeks.
- Subject has Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Subject has an unresectable or metastatic solid tumour or a local and resectable head and neck squamous cell carcinoma, or an unresectable stage III-IV melanoma.
- Subject is eligible for ICI treatment per Investigator judgement.
- Subject has at least 1 measurable tumour lesion documented on CT/magnetic resonance imaging (MRI) RECIST v1.1 during the last 12 months.
- Subject has a tumour lesion(s) of which a biopsy can safely be obtained according to standard clinical care procedures.
- Subject is male or female that agrees to adhere to the protocol contraception methods.
Exclusion Criteria:
- Subject is unable to undergo all procedures in the study and/or is unable to remain still and tolerate the imaging procedure.
- Subject has 12-lead ECG significant findings during screening, per Investigator's assessment.
- Subject is not stable due to medical condition or therapy that, in the opinion of the Investigator, could compromise subject safety or protocol objectives.
- Subject has active autoimmune disease or a documented history of autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents.
- Subject has serious non-malignant disease or conditions that, in the opinion of the Investigator, could compromise subject safety or protocol objectives.
- Subject has B or T cell lymphoma.
- Subject has brain or bone-marrow metastasis that, in the opinion of the Investigator, could compromise subject safety or protocol objectives.
- Subject has signs or symptoms of systemic infection within 2 weeks prior to imaging day.
- Subject has history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanised antibodies or fusion proteins or known allergy to the study IMP ingredients and/or the proposed ICI therapy.
- Subject has any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of the ICI treatment, or that may affect the interpretation of the results or render the subject at high risk from complications.
- Subject has laboratory values out of range per protocol.
- Subject has any safety laboratory test results (blood chemistry, haematology, and urinalysis) that, in the opinion of the Investigator, could compromise subject safety or protocol objectives.
- Subject has had any major surgery within 4 weeks prior to enrollment.
- Subject has been enrolled in another interventional clinical study within the 30 days before screening for this study, except for the study site IIS.
- Subject is pregnant or planning to become pregnant or is breastfeeding.
- Subject has a history of alcohol or drug abuse within the last year.
- Subject has had treatment with systemic immunostimulatory agents within 6 weeks or 5 half-lives of the drug, whichever is shorter, prior to dosing with the IMP.
- Subject has had treatment with systemic immunosuppressive medications within 2 weeks prior to dosing with the IMP.
- Subject has received acute, low-dose, systemic immunosuppressant medications that, in the opinion of the Investigator, could compromise protocol objectives.
- Subject has used systemic corticosteroids to treat inflammatory or autoimmune symptoms.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Diagnostiikka
- Jako: Ei satunnaistettu
- Inventiomalli: Peräkkäinen tehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Part A Cohort 1 - 1 mg dose
1 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together |
Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection. |
|
Kokeellinen: Part A Cohort 2 - 2 mg dose
2 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together |
Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection. |
|
Kokeellinen: Part A Cohort 3 - 4 mg dose
4 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together |
Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection. |
|
Kokeellinen: Part A Cohort 4 - 8 mg dose
8 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together |
Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection. |
|
Kokeellinen: Part A Cohort 5 (optional) - 12 or 15 mg dose
12 or 15 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together |
Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection. |
|
Kokeellinen: Part A Cohort 6 - Optimal dose
Selected (optimal) mass dose as determined from results of Cohorts 1 through 5 of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together |
Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection. |
|
Kokeellinen: Part B
Selected (optimal) dose of GEH200520 Injection from Part A with fixed dose of GEH200521 (18F) Injection administered together in 3 sequential repeat imaging visits |
Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush Whole-body PET/CT scan (up to 30 min). Exact timing will be determined from Part A. An optional dynamic scan may be acquired in addition to the required whole-body PET/CT scan at each imaging visit. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Aikaikkuna |
|---|---|
|
Osa A: Haitallisten haittavaikutusten esiintyminen syy-seuraussuhteeseen tutkimuslääkkeisiin.
Aikaikkuna: Osa A: 7 päivää
|
Osa A: 7 päivää
|
|
Osa A: AE vakavuus National Cancer Instituten Common Terminology Criteria for Adverse Events (NCI CTCAE versio 5.0) mukaan, jos syy-seuraus on tutkimuspotilaille.
Aikaikkuna: Osa A: 7 päivää
|
Osa A: 7 päivää
|
|
Arvioida aikakulun muutoksia GEH200521 (18F) -injektiossa immuunitarkistuspisteen estäjähoitojaksojen (ICI) jälkeen verrattuna lähtötilanteeseen.
Aikaikkuna: Osa B: 50 päivää
|
Osa B: 50 päivää
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
GEH200521 (18F) -injektion kiinteän annoksen säteilyannoksen arvioiminen erilaisten GEH200520 Injektiomassaannosten kanssa annettuna kumuloituneen aktiivisuuden perusteella lähdealueilla ja koko kehossa.
Aikaikkuna: 7 päivää
|
7 päivää
|
|
|
Optimaalisen kuvantamisaikaikkunan arvioiminen GEH200521 (18F) -injektiopositroniemissiotomografia (PET) -kuvaukselle, kun sitä annetaan erilaisten GEH200520 injektiomassaannosten kanssa osan A koehenkilöille.
Aikaikkuna: 7 päivää
|
7 päivää
|
|
|
Sopivan GEH200520-injektion massaannoksen määrittäminen GEH200521 (18F)-injektion kanssa hyväksyttävän PET-kuvanlaadun saavuttamiseksi osan A koehenkilöille.
Aikaikkuna: 7 päivää
|
7 päivää
|
|
|
Immunogeenisuuden arvioimiseksi hoidon indusoimien lääkkeiden vastaisten vasta-ainevasteiden ilmaantuvuuden kautta, yhden injektion jälkeen eri GEH200520-injektiomassaannoksilla, jotka on annettu kiinteällä annoksella GEH200521 (18F) -injektiota osan A koehenkilöille.
Aikaikkuna: 7 päivää
|
7 päivää
|
|
|
AE/SAE/AESI:n ilmaantuvuuden, vakavuuden ja käyntien välisten muutosten kerääminen
Aikaikkuna: 50 päivää
|
50 päivää
|
|
|
Arvioida GEH200521 (18F) -injektion biologista jakautumista ja kasvaimen sisäänottoa osassa A määritetyllä optimaalisella GEH200520 injektioannoksella GEH200521 (18F) kvantitatiivisten mittausten perusteella osan B koehenkilöille kiinnostavilla alueilla.
Aikaikkuna: 50 päivää
|
50 päivää
|
|
|
Kasvaimen GEH200521 (18F) -injektiokeräyksen (SUV-arvon) ja immuunisolujen CD8+-ekspressiopisteiden välisen suhteen arvioimiseksi biopsianäytteestä/resektoidusta leesiosta, kun se on saatavilla osan B koehenkilöiden IHC-tulosten perusteella.
Aikaikkuna: 50 päivää
|
50 päivää
|
|
|
Kasvaimen GEH200521 (18F) muutosten vertaaminen injektiokeräyksen muutoksiin tietokonetomografian (CT) kuvan arvioinnissa Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 mukaisesti osan B koehenkilöille, jos saatavilla.
Aikaikkuna: 50 päivää
|
50 päivää
|
|
|
Kasvaimen GEH200521 (18F) muutosten vertaaminen Injektiokeräyksen muutoksiin tietokonetomografian (CT) kuvan arvioinnissa [18F]-fluorodeoksiglukoosi (FDG) -skannausten mukaan, jos saatavilla osan B koehenkilöille.
Aikaikkuna: 50 päivää
|
50 päivää
|
|
|
Immunogeenisuuden vertaamiseksi hoidon aiheuttamien lääkkeiden vastaisten vasta-ainevasteiden ilmaantuvuuden kautta GEH200520-injektion useiden antamisen jälkeen GEH200521 (18F)-injektion kanssa osan B koehenkilöille.
Aikaikkuna: 50 päivää
|
50 päivää
|
|
|
To characterize the pharmacokinetic (PK) properties (AUC) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
Aikaikkuna: 7 days
|
The PK parameter to be assessed: AUC |
7 days
|
|
To characterize the pharmacokinetic (PK) properties (Cmax) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
Aikaikkuna: 7 days
|
The PK parameter to be assessed: Cmax |
7 days
|
|
To characterize the pharmacokinetic (PK) properties (CL) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
Aikaikkuna: 7 days
|
The PK parameter to be assessed: CL |
7 days
|
|
To characterize the pharmacokinetic (PK) properties (V) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
Aikaikkuna: 7 days
|
The PK parameter to be assessed: V |
7 days
|
|
To characterize the pharmacokinetic (PK) properties (t1/2) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
Aikaikkuna: 7 days
|
The PK parameter to be assessed: t1/2 |
7 days
|
|
Collection of the incidence, severity, changes between visits for AEs/SAEs/AESIs, for Part A subjects.
Aikaikkuna: 7 days
|
Incidence of AEs, SAEs, and Treatment-emergent AEs by system organ class and preferred term |
7 days
|
|
Changes in physical examination status following administration of GEH200520 and GEH200521 (18F) for Part A subjects
Aikaikkuna: Baseline, 24 hours, 7 days post IMP administration
|
The findings in the physical exam pre and post-administration will be summarized. |
Baseline, 24 hours, 7 days post IMP administration
|
|
Change from baseline in the results of serum biochemistry test results following administration of GEH200520 and GEH200521 (18F) for Part A subjects.
Aikaikkuna: Baseline, 24 hours, 7 days post IMP administration
|
In this context, baseline is defined as the pre-treatment assessment at the screening visit. The occurrence of post injection values outside of normal limits and changes from baseline will be summarized. |
Baseline, 24 hours, 7 days post IMP administration
|
|
Change from baseline in the results of haematology test results following administration of GEH200520 and GEH200521 (18F) for Part A subjects.
Aikaikkuna: Baseline, 24 hours, 7 days post IMP administration
|
Change from baseline in the results of haematology test results following administration of GEH200520 and GEH200521 (18F) for Part A subjects. |
Baseline, 24 hours, 7 days post IMP administration
|
|
Changes in heart rate as beats per minute following administration of GEH200520 and GEH200521 (18F) for Part A subjects
Aikaikkuna: Baseline, 2 hours, 24 hours, 7 days post IMP administration
|
The occurrence of post-administration heart rate values outside the normal limits will be summarized. |
Baseline, 2 hours, 24 hours, 7 days post IMP administration
|
|
Changes in blood pressure in mmHg following administration of GEH200520 and GEH200521 (18F) for Part A subjects
Aikaikkuna: Baseline, 2 hours, 24 hours, 7 days post IMP administration
|
The occurrence of post-administration blood pressure values outside the normal limits will be summarized. |
Baseline, 2 hours, 24 hours, 7 days post IMP administration
|
|
Changes in temperature as degree C following administration of GEH200520 and GEH200521 (18F) for Part A subjects
Aikaikkuna: Baseline, 2 hours, 24 hours, 7 days post IMP administration
|
The occurrence of post-administration body temperature values outside the normal limits will be summarized. |
Baseline, 2 hours, 24 hours, 7 days post IMP administration
|
|
Change from baseline in the results of 12-lead electrocardiograms (ECGs) following administration of GEH200520 and GEH200521 (18F) for Part A subjects
Aikaikkuna: Baseline, 2 hours, 24 hours, 7 days post IMP administration
|
Descriptive statistics will be used to describe the observed values and change from baseline. |
Baseline, 2 hours, 24 hours, 7 days post IMP administration
|
|
Changes in physical examination status following administration of GEH200520 and GEH200521 (18F) for Part B subjects
Aikaikkuna: Baseline, Day 15, Day 36, Day 50
|
The occurrence of post-administration physical exam status values outside the normal limits will be summarized. |
Baseline, Day 15, Day 36, Day 50
|
|
Change from baseline in the results of serum biochemistry test results following administration of GEH200520 and GEH200521 (18F) for Part B subjects.
Aikaikkuna: Baseline, Day 15, Day 36, Day 50
|
In this context, baseline is defined as the pre-treatment assessment at the screening visit. The occurrence of post injection values outside of normal limits and changes from baseline will be summarized. |
Baseline, Day 15, Day 36, Day 50
|
|
Change from baseline in the results of haematology test results following administration of GEH200520 and GEH200521 (18F) for Part B subjects.
Aikaikkuna: Baseline, Day 15, Day 36, Day 50
|
In this context, baseline is defined as the pre-treatment assessment at the screening visit. The occurrence of post injection values outside of normal limits and changes from baseline will be summarized. |
Baseline, Day 15, Day 36, Day 50
|
|
Changes in heart rate as beats per minute following administration of GEH200520 and GEH200521 (18F) for Part B subjects
Aikaikkuna: Baseline, Day 15, Day 36, Day 50
|
The occurrence of post-administration heart rate values outside the normal limits will be summarized. |
Baseline, Day 15, Day 36, Day 50
|
|
Changes in blood pressure in mmHg following administration of GEH200520 and GEH200521 (18F) for Part B subjects
Aikaikkuna: Baseline, Day 15, Day 36, Day 50
|
The occurrence of post-administration blood pressure values outside the normal limits will be summarized. |
Baseline, Day 15, Day 36, Day 50
|
|
Changes in temperature as degree C following administration of GEH200520 and GEH200521 (18F) for Part B subjects
Aikaikkuna: Baseline, Day 15, Day 36, Day 50
|
The occurrence of post-administration body temperature values outside the normal limits will be summarized. |
Baseline, Day 15, Day 36, Day 50
|
|
Change from baseline in the results of 12-lead electrocardiograms (ECGs) following administration of GEH200520 and GEH200521 (18F) for Part B subjects
Aikaikkuna: Baseline, Day 15, Day 36, Day 50
|
Descriptive statistics will be used to describe the observed values and change from baseline. |
Baseline, Day 15, Day 36, Day 50
|
|
To characterize the PK properties (AUC) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
Aikaikkuna: 50 days
|
The PK parameter to be assessed: AUC |
50 days
|
|
To characterize the PK properties (Cmax) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
Aikaikkuna: 50 days
|
The PK parameter to be assessed: Cmax |
50 days
|
|
To characterize the PK properties (CL) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
Aikaikkuna: 50 days
|
The PK parameter to be assessed: CL |
50 days
|
|
To characterize the PK properties (V) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
Aikaikkuna: 50 days
|
The PK parameter to be assessed: V |
50 days
|
|
To characterize the PK properties (t1/2) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
Aikaikkuna: 50 days
|
The PK parameter to be assessed: t1/2 |
50 days
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Opintojohtaja: Ravi Karra, MD, GE Healthcare
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- GE-269-001
- 2024-515218-42-00 (Ctis)
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .